世界中医药

目的：评价参菝抗瘤液联合化疗治疗晚期胃癌的临床疗效。方法：将40例晚期胃癌患者随机分为治疗组(参菝抗瘤液+化疗组)和对照组(化疗组)。对照组给予FOLFOX4方案化疗，治疗组同时加用参菝抗瘤液30 mL/d口服，连用1周，2周为一周期。结果：1）治疗组肿瘤近期客观疗效有效率高于对照组，但无统计学意义(P>0.05)；2）经治疗后，治疗组患者KPS评分升高率优于对照组，2组比较有统计学意义(P<0.01)；3）治疗组体重增加及稳定者比例均高于对照组，2组比较差异有统计学意义(P<0.05)；4）骨髓抑制比较，治疗组显著低于对照组(P<0.01)；5）消化道反应比较，治疗组明显低于对照组，化疗不良反应小(P<0.05)。结论：参菝抗瘤液联合化疗治疗晚期胃癌有改善生活质量，减轻化疗不良反应的作用。

English Summary:

To evaluate the effect of treating advanced gastric cancer with Shenba Kangliu Liquid combined with chemotherapy. Methods:Forty cases of advanced gastric cancer were randomly divided into the treatment group (Shenba Kangliu Liquid + chemotherapy) and the control group (chemotherapy). Patients in the control group were only received FOLFOX4, while Shenba Kangliu Liquid (30 ml/d, d1-14) was added for the first week for patients in the treatment group combined with chemotherapy as well and Shenba Kangliu Liquid was stopped in the second week. Two weeks were set as one course. Results:1) The effective rate of recent tumor objective efficacy in the treatment group was superior to that of the control group, showing no statistical significance (P>0.05). 2) KPS scores were significantly better in the treatment group than those in the control group. There was statistically significant difference (P<0.01). 3) Changes in weight gain and patients′ stability of the treatment group were better than those in the control group, showing statistical significance (P<0.05). 4) The bone marrow suppression of the treatment group was also lower than that of the control group (P<0.01). 5) The gastrointestinal reaction of the treatment group was obviously lower with fewer side effects than that of the control group, which indicated statistical significance (P<0.05). Conclusion:Treating advanced gastric cancer with Shenba Kangliu Liquid combined with chemotherapy may improve quality of life and reduce side effects from chemotherapy.

查看全文查看/发表评论下载PDF阅读器